Table 3. Differentially regulated miRNAs in DN patients.

miRNA	DN/C	raw P	adj. P	DN/T2D	raw P	adj. P	Function (sample matrix)	Target mRNA	PMID
miR-320c	4.83	<0.01	0.08	5.01	<0.01	0.16	Up-regulated in renal cortex of lupus nephritis patients (tissue).	THBS1, BMP1	18998140
miR-6068	3.85	<0.01	0.08	2.61	<0.01	0.41	—	—	—
miR-1234-5p	3.6	<0.01	0.08	2.5	0.02	0.51	Up-regulated in patients with minimal change disease (urine).	STAT3	25682967
miR-6133	2.95	<0.01	0.08	2.66	<0.01	0.41	—	SMAD7
miR-4270	2.87	0.02	0.36	2.97	0.04	0.59	Down-regulated in patients with focal segmental glomerulosclerosis (plasma).	NR1D2, LAMTOR	25682967
miR-4739	2.41	0.02	0.37	1.72	0.05	0.66	Induced expression in gastric cancer after interference with β-catenin (FFPE).	CTNNB1	25861021
miR-371b-5p	2.7	<0.01	0.32	1.93	0.02	0.52	Up-regulated in patients with lupus nephritis (PBMCs).	IRF5, TRIAP1	20485490
miR-638	2.71	<0.01	0.08	2.07	<0.01	0.41	Up-regulated in patients with lupus nephritis (PBMCs).	PGK1	20485490
miR-572	2.57	<0.01	0.08	2.14	<0.01	0.41	Increased in early state renal cell carcinoma (serum).	SOCS1, THBS1	25556603
miR-1227-5p	2.51	<0.01	0.24	2.06	0.01	0.41	Up-regulated in oncosomes produced by prostate cells (RWPE2 cells).	—	24091630
miR-6126	2.41	0.02	0.35	1.72	0.09	0.81	—	—	—
miR-1915-5p	2.25	0.03	0.44	1.51	0.18	0.93	Up-regulated in patients with minimal change disease (plasma).	TLR2	25682967
miR-4778-5p	2.17	0.01	0.35	2.21	0.01	0.41	—	STAT3	—
miR-2861	2.13	0.02	0.37	2.69	0.06	0.68	Up-regulated expression in papillary tyroid carcinoma with lymph node metastasis (tissue).	VEGF-A, FOXO1	23609190
miR-30e-5p	0.36	0.04	0.47	0.79	0.81	0.99	Down-regulation of miR-30 family is required for TGF-β induced apoptosis in podoytes.	PTPN13, FRMD6	24086574
miR-30d-5p	0.34	0.04	0.47	0.7	0.8	0.99	Down-regulation of miR-30 family is required for TGF-β induced apoptosis in podoytes.	STAT3, TNF	24086574